secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aclaris Therapeutics, Inc. (ACRS)
CIK:        0001557746
Form:       8-K
Filed at:   2025-11-06T23:59:59+00:00
Accession:  0001104659-25-107353
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aclaris Therapeutics Q3 net loss widens to $14.6M; cash $167.2M; pipeline updates
--------------------------------------------------------------------------------

- Net loss $14.6M in Q3 2025 vs $7.6M in Q3 2024; total revenue $3.3M vs $4.3M.
- Cash, equivalents and marketable securities $167.2M as of Sep 30, 2025, funding into H2 2028.
- Positive Phase 2a results for ATI-2138 in AD; Phase 2 trial in additional indication expected H1 2026.
- Top line results for bosakitug (Phase 2 AD) expected H2 2026; ATI-052 Phase 1b POC in asthma/AD expected H1 2026.
- R&D expenses rose to $13.0M (vs $6.0M) driven by clinical and preclinical activities.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1557746/000110465925107353/0001104659-25-107353-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1557746/000110465925107353/acrs-20251106x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-107353

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer